2025
Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib
Mostaghimi A, Craiglow B, King B, Shapiro J, Ko J, Tosti A, Ohyama M, Brogan Y, Yu G, Sontag A, Somani N. Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib. British Journal Of Dermatology 2025, ljaf088. PMID: 40179237, DOI: 10.1093/bjd/ljaf088.Peer-Reviewed Original ResearchBaricitinib 4 mgBaricitinib 2 mgHair-bearing sitesAlopecia areataResponse rateBenefit of baricitinibTreated with baricitinibRandomised to placeboPlacebo-controlled trialResponse to treatmentScalp hair lossSALT scoreDouble-blindClinical presentationBaricitinib treatmentTreatment successHair regrowthBaricitinibBaseline severityPatientsClinician reportsHair lossPlaceboPooled dataScalp
2022
Application of longitudinal item response theory models to modeling Parkinson’s disease progression
Zou H, Aggarwal V, Stebbins G, Müller M, Cedarbaum J, Pedata A, Stephenson D, Simuni T, Luo S. Application of longitudinal item response theory models to modeling Parkinson’s disease progression. CPT Pharmacometrics & Systems Pharmacology 2022, 11: 1382-1392. PMID: 35895005, PMCID: PMC9574723, DOI: 10.1002/psp4.12853.Peer-Reviewed Original ResearchConceptsEarly Parkinson's diseaseParkinson's diseaseDisease progressionProgression rateUnified Parkinson's Disease Rating Scale part 2Stage 1Yahr stage 1Higher baseline severityCommon clinical outcomeLongitudinal disease progressionSlow progression rateParkinson's disease progressionMovement Disorder SocietyStage 2Clinical outcomesMotor signsBaseline severitySlow progressionSum scoreTotal scoreLongitudinal item response theory modelProgressionSeverityPatientsDisease
2021
Electroencephalography, Hospital Complications, and Longitudinal Outcomes After Subarachnoid Hemorrhage
Lissak IA, Locascio JJ, Zafar SF, Schleicher RL, Patel AB, Leslie-Mazwi T, Stapleton CJ, Koch MJ, Kim JA, Anderson K, Rosand J, Westover MB, Kimberly WT, Rosenthal ES. Electroencephalography, Hospital Complications, and Longitudinal Outcomes After Subarachnoid Hemorrhage. Neurocritical Care 2021, 35: 397-408. PMID: 33483913, PMCID: PMC7822587, DOI: 10.1007/s12028-020-01177-x.Peer-Reviewed Original ResearchConceptsHospital-acquired infectionsHospital complicationsEpileptiform abnormalitiesSubarachnoid hemorrhageCerebral ischemiaLongitudinal outcomesContinuous EEGNon-traumatic subarachnoid hemorrhageTime pointsNontraumatic subarachnoid hemorrhageEffects modelCumulative proportional odds modelRankin ScaleProspective studyFunctional outcomeResultsIn totalBaseline severityCEEG monitoringTherapeutic targetComplicationsSustained impairmentMRS assessmentSecondary analysisLongitudinal assessmentMixed effects models
2018
Long-term outcomes of mitral regurgitation by type and severity
Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, Alexander JH, Kisslo JA, Wang A, Mark DB, Velazquez EJ. Long-term outcomes of mitral regurgitation by type and severity. American Heart Journal 2018, 203: 39-48. PMID: 30015067, DOI: 10.1016/j.ahj.2018.05.001.Peer-Reviewed Original ResearchConceptsMR severityCause deathIschemic MRSurvival rateCause death riskCoronary artery diseaseLong-term outcomesAbsolute mortality ratesQualifying patientsArtery diseaseEchocardiography studyMitral regurgitationVentricular sizeIndeterminate causeBaseline severityDeath riskSevere MREchocardiography laboratoryHigh riskMortality rateClinical settingPatientsValve morphologySeverityMyxomatous
2017
Impact of Multisystem Health Care on Readmission and Follow-up Among Veterans Hospitalized for Chronic Obstructive Pulmonary Disease
Rinne ST, Elwy AR, Bastian LA, Wong ES, Wiener RS, Liu CF. Impact of Multisystem Health Care on Readmission and Follow-up Among Veterans Hospitalized for Chronic Obstructive Pulmonary Disease. Medical Care 2017, 55: s20-s25. PMID: 28288076, DOI: 10.1097/mlr.0000000000000708.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseNon-VA careObstructive pulmonary diseaseOutpatient carePulmonary diseaseReadmission riskRetrospective cohort studyDays of dischargeNon-VA providersHealth careVeterans Affairs hospitalAssociation of useVA administrative dataMixed-effects logistic regressionMedicare-eligible veteransOutcomes of interestCause readmissionIndex hospitalizationPostdischarge outcomesCohort studyBaseline severityCOPD readmissionsFollow-upWorse outcomesCommon cause
2016
RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER
Otto MW, Pollack MH, Dowd SM, Hofmann SG, Pearlson G, Szuhany KL, Gueorguieva R, Krystal JH, Simon NM, Tolin DF. RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER. Depression And Anxiety 2016, 33: 737-745. PMID: 27315514, PMCID: PMC5958622, DOI: 10.1002/da.22531.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyBenzodiazepine usePanic disorderDCS augmentationMulticenter trialD-cycloserineRecent multicenter trialPanic Disorder Severity ScaleExposure-based cognitive-behavioral therapySessions of treatmentStudy pillsPrimary outcomeRandomized trialsBaseline severityPrimary diagnosisAugmentation effectTreatment responseTreatment endpointBooster sessionsSeverity ScaleRole of severityBehavioral therapyDCS efficacyBeneficial effectsPilot study
2011
Low Body Temperature Does Not Compromise the Treatment Effect of Alteplase
Lees JS, Mishra NK, Saini M, Lyden PD, Shuaib A. Low Body Temperature Does Not Compromise the Treatment Effect of Alteplase. Stroke 2011, 42: 2618-2621. PMID: 21757664, DOI: 10.1161/strokeaha.110.611210.Peer-Reviewed Original ResearchConceptsBaseline body temperatureAcute ischemic strokeRankin Scale scoreIschemic strokeAlteplase treatmentBaseline severityBody temperatureScale scoreVirtual International Stroke Trials ArchiveRankin Scale distributionsBaseline National InstitutesHealth Stroke ScaleIschemic stroke modelTreatment effectsStroke ScaleThrombolytic therapyImproved outcomesTherapeutic effectTreatment responseStroke modelTreatment groupsAlteplaseCochran-MantelLow body temperatureStrokeHome Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy
Mishra NK, Shuaib A, Lyden P, Diener HC, Grotta J, Davis S, Davalos A, Ashwood T, Wasiewski W, Lees KR. Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy. Stroke 2011, 42: 1046-1050. PMID: 21350199, DOI: 10.1161/strokeaha.110.601302.Peer-Reviewed Original ResearchConceptsHealth Stroke ScaleBaseline National InstitutesPresence of diabetesAcute stroke trialsStroke ScaleRankin ScaleBarthel IndexStroke trialsNational InstituteDay 90Use of alteplaseHome timeCountry of enrollmentLevel of consciousnessAlteplase useIschemic strokeStroke onsetIschemic lesionsThrombolytic therapyPatient enrollmentBaseline severityOrdinal logistic regressionTreatment responsivenessOutcome measuresAnalysis of covariance
2010
Influence of Age on Outcome From Thrombolysis in Acute Stroke
Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR. Influence of Age on Outcome From Thrombolysis in Acute Stroke. Stroke 2010, 41: 2840-2848. PMID: 21030710, DOI: 10.1161/strokeaha.110.586206.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeHealth scale scoresControl subjectsIschemic strokeInfluence of ageScale scoreBaseline National InstitutesRankin Scale scoreNational InstituteLimited trial dataNeuroprotection trialsRankin scoreThrombolysis treatmentAcute strokeYounger patientsAge decilesPoor outcomeBaseline severityImproved outcomesPatientsHaenszel testTrial dataCochran-MantelThrombolysisLogistic regressionThrombolysis Is Associated With Consistent Functional Improvement Across Baseline Stroke Severity
Mishra NK, Lyden P, Grotta JC, Lees KR. Thrombolysis Is Associated With Consistent Functional Improvement Across Baseline Stroke Severity. Stroke 2010, 41: 2612-2617. PMID: 20947852, DOI: 10.1161/strokeaha.110.589317.Peer-Reviewed Original ResearchConceptsRankin Scale score distributionBaseline stroke severityBaseline NIHSSAssociation of treatmentScale score distributionStroke severityOdds ratioModified Rankin scale score distributionCochran-MantelVirtual International Stroke Trials ArchiveBaseline National InstitutesConsistent functional improvementsHealth Stroke ScaleProportional odds logistic regression analysisClinical trial enrollmentLogistic regression analysisNeuroprotection trialsUntreated comparatorsStroke ScaleTrial enrollmentAdjusted outcomesThrombolysed patientsNonrandomized comparisonBaseline severityFunctional improvement
2007
Aripiprazole as an adjunctive treatment for refractory unipolar depression
Hellerstein DJ, Batchelder S, Hyler S, Arnaout B, Corpuz V, Coram L, Weiss G. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2007, 32: 744-750. PMID: 18164528, DOI: 10.1016/j.pnpbp.2007.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsAripiprazoleBrief Psychiatric Rating ScaleDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleDrug EvaluationFemaleHumansMaleMiddle AgedPiperazinesProspective StudiesQuinolonesSocial BehaviorTime FactorsTreatment OutcomeConceptsHDRS-24Adjunctive treatmentSNRI medicationsUnipolar depressionCurrent episodeWeek open label studyTreatment-resistant major depressionCurrent DSM-IV diagnosisEffectiveness of aripiprazoleRefractory unipolar depressionOpen-label studyEffective adjunctive treatmentDSM-IV diagnosisFluoxetine equivalentsSNRI treatmentWeek 12Baseline severityMean doseMajor depressionTreatment respondersSide effectsSSRIsMaximum doseAripiprazoleMedications
1999
Concurrent and Predictive Validity of Antisocial Personality Disorder Subtyping among Substance Abusers
CECERO J, BALL S, TENNEN H, KRANZLER H, ROUNSAVILLE B. Concurrent and Predictive Validity of Antisocial Personality Disorder Subtyping among Substance Abusers. The Journal Of Nervous And Mental Disease 1999, 187: 478-486. PMID: 10463065, DOI: 10.1097/00005053-199908000-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAntisocial Personality DisorderChi-Square DistributionComorbidityDepressive DisorderDiagnosis, Dual (Psychiatry)Follow-Up StudiesHospitalizationHumansMental DisordersMultivariate AnalysisPersonality InventoryProbabilityPsychiatric Status Rating ScalesPsychometricsReproducibility of ResultsSeverity of Illness IndexSubstance-Related DisordersConceptsAntisocial personality disorderAdult antisocial behaviorLifetime depressionPsychiatric severityFull ASPDSubstance abusersPersonality disorderHistory of depressionAxis II pathologyOutpatient substance abusersPoor prognosisBaseline severityGreater baselineSubstance useSeverityDisordersStrongest predictorDepressionMultivariate regressionSubtypesBaselinePredictive validityAbusersVersusPrognosis
1998
Drug abuse treatment success among needle exchange participants.
Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D. Drug abuse treatment success among needle exchange participants. Public Health Reports 1998, 113 Suppl 1: 129-39. PMID: 9722818, PMCID: PMC1307735.Peer-Reviewed Original ResearchConceptsNeedle exchange programsOpioid agonist treatment programStandard referral groupTreatment programReferral groupBetter short-term treatment outcomesNew admissionsDrug useHuman immunodeficiency virus (HIV) transmissionShort-term treatment outcomesDrug abuse treatment clinicsGreater baseline severitySelf-reported drug useDrug abuse treatment programsUse of drugsReferral patientsClinical variablesBaseline severityIncidence rateTreatment successTreatment clinicsTreatment outcomesBaseline differencesTreatment responseOutcome measures
1994
Psychotherapy and Pharmacotherapy for Ambulatory Cocaine Abusers
Carroll KM, Rounsaville BJ, Gordon LT, Nich C, Jatlow P, Bisighini RM, Gawin FH. Psychotherapy and Pharmacotherapy for Ambulatory Cocaine Abusers. JAMA Psychiatry 1994, 51: 177-187. PMID: 8122955, DOI: 10.1001/archpsyc.1994.03950030013002.Peer-Reviewed Original ResearchConceptsClinical managementCocaine useCocaine abusersRelapse preventionAmbulatory cocaine abusersWeeks of treatmentForm of treatmentHigh-severity patientsInitiation trialsAbstinence initiationBaseline severityClinical trialsEffective treatmentTreatment retentionBetter outcomesCocaine abusePharmacotherapyDepressed subjectsPlaceboDesipramine hydrochlorideSpecialized treatmentDesipraminePreventionGreater reductionDistinct subgroups
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply